reactions, most commonly oxidations and glycosylations, carried out by dedicated tailoring enzymes en-and Molecular Pharmacology Harvard Medical School coded with the assembly line genes in biosynthetic gene clusters [1, 8]. The glycosylations may be required Boston, Massachusetts 02115 2 Department of Chemistry and for gain of biological activity, as in the erythromycin family [9], or as scaffolds for further enzymatic decora-The Skaggs Institute for Chemical Biology The Scripps Research Institute tion to create the pharmacophores [10]. We have focused on characterization of such glycosyltransferases 10550 North Torrey Pines Road La Jolla, California 92037
substrate in tyrocidine synthetase [3] . The head-to-tail harvard.edu 3 These authors contributed equally to this work. cyclization is shown in Figure 2 for both the wild-type Table 2) .
Substitution of Tyr 7 by Ser or any of four glycosyl-serines, including N-acetyl-glucosaminyl-and 2-amino-2-deoxy-Biological Activity of Glycosylated glucosyl-O-Ser 7 , could be done without substantial Tyrocidine Derivatives penalty for subsequent head-to-tail macrocyclization
The antibiotic activity of tyrocidine arises from its peneby the enzyme. This suggests a prospect of subsetration into bacterial membranes and subsequent pore quent chemical and/or enzymatic acylation strategies formation. The selectivity of bacterial membranes verto make cyclic lipoglycopeptides by these approaches. sus eukaryotic membranes is not particularly high, lim-In terms of the cyclization to hydrolysis ratio mediated iting the systemic use of this class of cyclic peptide by the TE domain, the Tyr 7 (β-D-Gal) and Tyr 7 (β-D-Glc) antibiotics [20] . We evaluated the minimal inhibitory substrates gave ratios of 8:1-10:1 under conditions in concentration (MIC) against Bacillus subtilis and the which the Tyr 7 wild-type decapeptidyl-S-NAC sequence minimal hemolytic concentration (MHC) against human was cyclized at ratios of 12:1-17:1. These ratios provide erythrocytes as a typical eukaryotic cell membrane toxsynthetically useful flux to regiospecific macrocyclizaicity [21, 22] . As shown in Table 3 , the MIC for the partion of the monoglycosylated peptides. Table 1 Assay conditions were the same as in Table 1. tention of regiospecific macrocyclization capacity [3, 7, terfere noticeably with the D-Phe 1 -L-Leu 10 enzymatic macrocyclization.
16-19]. Since many nonribosomal peptides undergo post-We do not expect a priori for glycosylation of the membrane-seeking cyclic tyrocidine peptides to im-assembly line tailoring by dedicated glycosyltransferases [1, 8, 24] to create glycopeptides in which solubil-prove either antibiotic efficacy or necessarily reduce the liability of nonspecific pore formation in eukaryotic ity and/or biological activity is altered by the tailoring process, we have begun to explore in this work whether membranes (measured as hemolysis of human red cells). In fact, most of the glycosylated tyrocidines re-one could provide glycosylated substrates to this TE domain and still see effective head-to-tail cyclization.
tained their antibiotic activity with equal or marginally decreased tendency to hemolysis. These initial data To that end, we have replaced each of residues 5-8 with a serine side chain and observed maintenance of suggest that one could create libraries of glycosylated peptides to evaluate these and other biological activ-good ratios of enzymatic cyclization to hydrolysis of the serine-containing peptidyl thioesters. Our initial focus ities.
Using the combination of chemoenzymatic steps on Tyr 7 shows that incorporation of Tyr(β-D-Gal) or Tyr (β-D-Glc) during solid-phase synthesis of the decapep-
noted here, it should be feasible to make libraries of cyclic tyrocidine peptides with monosaccharides or oli-tidyl-S-NACs caused no problem for enzyme-directed flux of head-to-tail cyclization. Furthermore, four dif-gosaccharides at multiple residues. However, there is no reason to believe this approach is limited to the tyro-ferent β-glycosyl-Ser 7 substitutions for Tyr 7 were also not deleterious to TE-mediated flux to macrolactamiza-cidine synthetase TE. We and others have noted that TE domains excised from additional NRPS assembly tion. Subsequently, we substituted Ser(β-D-Gal) in deprotected or tetra-O-acetyl-protected forms at each of lines [4-6] retain stereo-and regiospecificity as catalysts to make branched macrocycles, both macrolac-residues 5-8. Only at residue 8 did the substitution intams and macrolactones. Therefore, libraries of glycopeptides on different peptide scaffolds should be accessible by use of glycosyl amino acids in solid- bones of hybrid polyketide/nonribosomal peptides to activity. An alternative to nature's use of tandem enzymatic steps of macrocyclization and glycosylation N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4,6-tetra-O-acetyl-␤ N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4 
General Procedures for Chemical Synthesis

,6-tetra-O-acetyl-␤-D-All chemicals were purchased as reagent grade and were used glucopyranosyl)-L-serine Allyl Ester (2a) without further purification. Dichloromethane (CH 2 Cl 2 ) was distilled
Compound 2a was prepared by reaction of Fmoc-Ser-OAll (414 mg, over calcium hydride, and tetrahydrofuran (THF) and diethyl ether 1.13 mmol, 1 eq) and β-D-glucose pentaacetate (1.3 g, 3.33 mmol, were distilled over sodium/benzophenone ketyl. Anhydrous DMF 3 eq) in dry CH 2 Cl 2 under BF 3 ·OEt 2 promotion at 4°C by adding the was purchased from a commercial source. Reactions were moniglycosyl donor in three separate 1 eq additions according to the tored with analytical thin-layer chromatography (TLC) on silica gel general procedure. The reaction was monitored by TLC with 25% 60 F254 plates and visualized under UV (254 nm) and/or by staining ethyl acetate/hexanes run three times, R f = 0.08: (346 mg, 44%); with acidic cerium ammonium molybdate. 1 N-(9-Fluorenylmethoxycarbonyl)-3-O-(2,3,4 N-(9-Fluorenylmethoxycarbonyl)-3-O-(2-deoxy-2-(2,2,2 2.72 mmol, 1 eq) and 1,3,4,6-tetra-O-acetyl-2-deoxy-2-(2#,2#,2# N-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-␤-D-(1.8 g, 88%) ; R f = 0.2 (40% ethyl acetate/hexanes); spectral data galactopyranosyl)-L-tyrosine Allyl Ester (5a) are in agreement with those reported [28] .
,6-tetra-O-acetyl-␤-Dacceptor remained, additional glycosyl donor (1 eq) and BF 3 ·OEt 2 glucopyranosyl)-L-serine (2b)
Compound 5a was prepared by reaction of Fmoc-Tyr-OAll (113.4  mg, 0.26 mmol, 1 eq) and β-D-galactose pentaacetate (300.5 mg, 0.77 mmol, 3 eq) in dry CH 2 Cl 2 under BF 3 ·OEt 2 promotion at 4°C N-(9-Fluorenylmethoxycarbonyl)-3-O-(2-acetamido-3,4,6-tri-O- by adding the glycosyl donor in three separate 1 eq additions acacetyl-2-deoxy-␤-D-glucopyranosyl)-L-serine Allyl Ester (3a)
cording to the general procedure (138 mg, 70%) . The reaction was Glycosyl amino acid 3 (150 mg, 0.18 mmol) 
N-(9-Fluorenylmethoxycarbonyl)-3-O-(2-acetamido-3,4,6-tri-O-N-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-␤-Dacetyl-2-deoxy-␤-D-glucopyranosyl)-L-serine (3b)
galactopyranosyl)-L-tyrosine (5b) Compound 3b was prepared by reaction of 3a (63 mg, 0.09 mmol)
Compound 5b was prepared by reaction of 5a (70 mg, 0.09 mmol) with Pd(PPh 3 ) 4 (1.05 mg, 0.9 mol) and morpholine (15 l, 0.17 with Pd(PPh 3 ) 4 (1.05 mg, 0.9 mol) and morpholine (15 l, 0.17 mmol) in CH 2 Cl 2 (500 l) according to the general procedure, exmmol) in CH 2 Cl 2 (500 l) according to the general procedure; cept the workup was done with only one wash with 10% citric acid; spectral data are in agreement with those reported [26] . spectral data are in agreement with those reported [28] . N-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-␤-D-N-(9-Fluorenylmethoxycarbonyl)-3-O-(3,4,6-tri-O-acetyl-2-tert 41 (s, 9H, t-Bu), 2.02, 2.04, 2.06 (3s, 3H each, Ac) 1H, H-2), 3.6-3.7 (m, 1H, H-5), 3.90 (dd, 1H, J = 2.5 and 10.5, H-β 10 (dd, 1H, J = 2.0 and 12.5, H-6), 4.2-4.3 (m, 3H, H-6#, H-β# 56 (m, 1H, H-α), 4.6-4.7 (m,  N-(9-Fluorenylmethoxycarbonyl)-O-(2,3,4,6-tetra-O-acetyl-␤-D-2H, allyl OCH 2 ), 4.74 (br d, 1H, H-1 N-(9-Fluorenylmethoxycarbonyl)-3-O-(3,4,6-tri-O-acetyl-2- 40 (s,  9H, t-Bu), 2.01, 2.03, 2.06 (3s, 3H each, Ac), 3.55 (m, 1H, H-2 (m, 1H, H-α), 4.69 (br d, 1H, H-1 24 (m, 1H, H-3), 6.00 (d, 1H, J = 8.0 Hz, NH), 7.3-7.8 (m, t,  dd, d, 8H, Fmoc Ar) ; MALDI-MS of C 35 H 42 N 2 O 14 (M, 715) m/z 738 resin, filtered, and concentrated. Alternatively, the acetyl protecting groups can be removed with 1:7 hydrazine hydrate (55%):methanol well. After overnight incubation at 30°C, the concentrations required for complete inhibition of bacterial cell growth were deter-for 5 hr before cleavage of the peptide from the solid support.
Synthesis of Linear Peptide N-acetylcysteamine Thioesters
To make the N-acetylcysteamine thioester, the peptides (25 mined by visual inspection. Minimal hemolytic concentration (MHC) values were determined by the addition of 80 µl of human red blood mol) were mixed with NAC (53 l, 500 mol), dicyclohexylcarbodiimide (16 mg, 75 mol), HOBt (12 mg, 75 mol), and diisopropyleth-cells (Research Blood Components) diluted (1/100) with PBS buffer (pH 7.4) to dried peptides. RBCs were incubated at room temper-ylamine (17 l, 100 mol) in THF (0.5 ml). The reaction was agitated at room temperature for 3 hr to overnight. After removal of the THF, ature overnight, and concentrations required for complete lysis were determined visually. the peptide thioesters were deprotected with 95:5:5 TFA:water:triisopropylsilane (2 ml) or 16:3:1 TFA:CH 2 Cl 2 :NAC at ambient temperature for 4 hr. Then the peptide thioesters were precipitated with cold ether (40 mL), and the precipitates were collected by centrifu-
